Biodesix Finds $8.3M In Series E Funding

Boulder-based molecular diagnostics provider Biodesix said this morning that it has raised $8.3M in a Series E equity funding round. The company said the funding was split between 44.3M in new capital, plus $4M in conversion of a convertible note. The funding came from the company's existing investors, who were not named by the company. Biodesix is developing diagnostic testing technology, with a first focus on advanced non-small cell lung cancer (NSCLC). The firm is led by David Brunel. More information »